ReviewMedical cannabis and cannabinoids2020
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions.
Review in Medical cannabis and cannabinoids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis.Addiction (Abingdon, England) · 2026Pooled it
- The Influence of CBD and THC on Hepatic Enzymes of the Human Cytochrome P450 Complex Family: A Systematic Literature Review.European journal of drug metabolism and pharmacokinetics · 2026Pooled it
- Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, andFrontiers in pharmacology · 2024Pooled it
- The effect of nightly use of 150 mg cannabidiol on daytime neurocognitive performance in primary insomnia: a randomized controlled pilot trial.Psychopharmacology · 2025Trial
- Differences in Plasma Cannabidiol Concentrations in Women and Men: A Randomized, Placebo-Controlled, Crossover Study.International journal of molecular sciences · 2023Trial
- Healthcare Providers' Acceptability of Cannabis And Cannabidiol to Manage Parkinson's Disease in France.Current therapeutic research, clinical and experimental · 2026Article
- Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and Permeation Enhancement.AAPS PharmSciTech · 2026Review
- Age and Gender Heterogeneity in Adverse Drug Reactions Associated with Hemp Use: Evidence from the FDA Pharmacovigilance Data in the Last Two Decades.Drugs - real world outcomes · 2026Article
- An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans.Pharmaceutics · 2025Review
- Rural reticence to inform physicians of cannabis use.The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association · 2025Article
- Chemical Transformation of Vaping Emissions under Indoor Atmospheric Aging Processes.Chemical research in toxicology · 2025Article
- Rastafarianism: When Religious Beliefs Conflict With Medical Necessity-A Case Report and Review of the Literature Around an Ethically Complicated Case.Case reports in psychiatry · 2025Article
- Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey.Parkinson's disease · 2025Article
- Unveiling the impact of water-boiled cannabis on warfarin: A case report of atrial fibrillation patients after cannabis legalization in Thailand.Toxicology reports · 2024Article
- Article
- A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance.Neuropsychopharmacology reports · 2024Article
- Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.Frontiers in pharmacology · 2024Article
- Cannabis as a Source of Approved Drugs: A New Look at an Old Problem.Molecules (Basel, Switzerland) · 2023Review
- Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Combination with Morphine Using the Formalin Test in Male and Female Mice.Cannabis and cannabinoid research · 2022Article
- Lessons for the clinical nephrologist: unexplained tacrolimus overdose in a kidney transplant patient.Journal of nephrology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although prescribing information (PI) is often the initial source of information when identifying potential drug-drug interactions, it may only provide a limited number of exemplars or only reference a class of medications without providing any specific medication examples. In the case of medical cannabis and medicinal cannabinoids, this is further complicated by the fact that the increased therapeutic use of marijuana extracts and cannabidiol oil will not have regulatory agency approved PI. The objective of this study was to provide a detailed and comprehensive drug-drug interaction list that is aligned with cannabinoid manufacturer PI. The cannabinoid drug-drug interaction information is listed in this article and online supplementary material as a PRECIPITANT (cannabinoid) medication that either INHIBITS/INDUCES the metabolism or competes for the same SUBSTRATE target (metabolic enzyme) of an OBJECT (OTHER) medication. In addition to a comprehensive list of drug-drug interactions, we also provide a list of 57 prescription medications displaying a narrow therapeutic index that are potentially impacted by concomitant cannabinoid use (whether through prescription use of cannabinoid medications or therapeutic/recreational use of cannabis and its extracts).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.